We are at an inflection point in cancer research today. New biological models now more closely mimic the behavior of cancer and are standardized, annotated, traceable, and paired with genomic and phenotypic data. These new advanced cancer models are contributing more valuable and reproducible research results than ever before.

Human Cancer Models Initiative (HCMI)

As part of our pledge to elevate biological models, ATCC is collaborating with HCMI to offer scientists a wide variety of next-generation 2-D and 3-D patient-derived in vitro cancer models, including organoids, neuronal models, and conditionally reprogrammed cells. 

Isogenic Cell Models

Clinically relevant cell models are critical for studies of molecular and cellular mechanisms of tumors, as well as for drug screening for cancer. Using CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes, which are ideal for identifying novel, personalized treatment regimens.

Epithelial-mesenchymal Transition (EMT)

CRISPR-edited EMT and mesenchymal-epithelial transition (MET) reporter cell lines enable real-time monitoring of the transition of cells from epithelial to mesenchymal state (or the reverse) via the expression of red fluorescent protein (RFP)–tagged vimentin or green fluorescent protein (GFP)–tagged E-cadherin.

Luciferase

ATCC is bridging the gap between the in vitro and the in vivo by offering luciferase-labeled cell lines for biological mechanism studies and drug development; these advanced models provide a relatively simple, robust, and highly sensitive means to measure biological processes and to assess drug efficacy in live animal models through bioluminescence imaging.

Organoids

Organoids are self-organizing microtissues that serve as invaluable preclinical models for studying cancer and offer many advantages over existing human or non-human animal cancer models.

Explore the advanced cancer models in our collection.